All relevant data are within the paper.

Introduction {#sec005}
============

Hyponatremia is the most common disorder of body fluid and electrolyte balance in hospitalized patients \[[@pone.0162990.ref001]\]. The presence of hyponatremia is hazardous since it is associated with increased risk of mortality in hospitalized patients \[[@pone.0162990.ref002]\], including those with heart \[[@pone.0162990.ref003]\] and liver \[[@pone.0162990.ref004]\] diseases, stroke \[[@pone.0162990.ref005]\], and chronic kidney disease (CKD) \[[@pone.0162990.ref006], [@pone.0162990.ref007]\]. According to recent meta-analysis, hyponatremic subjects showed a 2.6 times higher risk of death than non-hyponatremic subjects, even when the decrease in the serum sodium level was moderate \[[@pone.0162990.ref008]\].

Acute kidney injury (AKI) is also a common, but harmful disease \[[@pone.0162990.ref009]\]. As with hyponatremia, the presence of AKI is dangerous since it predicts mortality in critically or non-critically ill hospitalized patients \[[@pone.0162990.ref010], [@pone.0162990.ref011]\] and in community based patients \[[@pone.0162990.ref012]\]. There are several causes of AKI such as volume depletion \[[@pone.0162990.ref013]\] or overload \[[@pone.0162990.ref014], [@pone.0162990.ref015]\], sepsis \[[@pone.0162990.ref016]\], and heart \[[@pone.0162990.ref017]\] and liver \[[@pone.0162990.ref018]\] disease. Hyponatremia is also frequently developed in conditions with volume imbalances which can provoke the development of AKI \[[@pone.0162990.ref001], [@pone.0162990.ref019], [@pone.0162990.ref020]\]. Once AKI is developed, the chances of fluid overload and overcorrection of hyponatremia are increasing \[[@pone.0162990.ref021], [@pone.0162990.ref022]\], and thus extra-cautions for the treatment of electrolyte imbalance are warranted.

Under specific conditions such as cancer, cardiorenal syndrome, and liver transplantation, hyponatremia has been correlated with the development of AKI \[[@pone.0162990.ref023]--[@pone.0162990.ref025]\]. In contrast, cross-talk between pre-existing hyponatremia and hospital acquired AKI in a large cohort study has been sparsely investigated \[[@pone.0162990.ref026], [@pone.0162990.ref027]\]. Therefore, we investigated whether pre-existing hyponatremia could predict the development of AKI, and whether AKI and hyponatremia have a combined effect on patient mortality using data from an 1-year administrative cohort.

Material and Methods {#sec006}
====================

Patients {#sec007}
--------

We collected data from 21572 adult patients aged 18 years or older, whose serum creatinine was identified once or more during their first admission for 1 year in 2013 at a tertiary care hospital, Seongnam, Korea ([Fig 1](#pone.0162990.g001){ref-type="fig"}). Among these, 19592 patients were eligible for the study after excluding patients with missing sodium data (n = 453), known end stage renal disease (ESRD, n = 309) and community acquired AKI (n = 1218). Of the remaining 19592 patients, we only included 19191 patients after further excluding 401 patients with hypernatremia at admission since hypernatremia is another independent risk factor of mortality \[[@pone.0162990.ref028]\] and is beyond the scope of this study. The study protocol complies with the Declaration of Helsinki and received full approval from the Seoul National University Hospital\`s institutional review board (IRB number: B-1511/322-112), which waived the need for informed consent since the study did not infringe on patient privacy or health status.

![Algorithm for eligible patient selection.\
Hypernatremia is defined as sodium 145 mmol/L or higher. ESRD, end stage renal disease; AKI, acute kidney injury.](pone.0162990.g001){#pone.0162990.g001}

Definitions and measurements {#sec008}
----------------------------

Demographic, physiological, and laboratory data at the index admission were gathered from the electronic medical records database. After different patient datasets were merged, data verification was performed manually. Hypertension was defined as the presence of a physician diagnosis or receiving anti-hypertensive drugs. Anti-hypertensive drugs included alpha and beta blockers, calcium channel blockers, renin angiotensin system (RAS) inhibitors, and diuretics. Diabetes was defined as physician diagnosis or being prescribed insulin or oral anti-diabetic drugs. Cardiovascular disease was defined as a physician diagnosis of angina, ischemic heart disease, myocardial infarction or cerebrovascular disease. Body mass index was calculated as weight (kg) per square of height (m^2^). Biochemistry analysis including serum glucose was performed using random blood or urine samples. For the inflammatory markers, we used white blood cell counts, red cell distribution width (RDW) \[[@pone.0162990.ref011]\], neutrophil to lymphocyte ratio (NLR) \[[@pone.0162990.ref029]\], and C-reactive protein (CRP).

Using the first serum sodium level of the index admission, we defined hypo- and hypernatremia as serum sodium \< 135 mmol/L \[[@pone.0162990.ref001]\] and ≥ 145 mmol/L \[[@pone.0162990.ref030]\], respectively. Among 19191 patients, 18353 had serial data of serum sodium levels during their index admission. De novo hypernatremia was defined as at least one event of hypernatremia during the hospital stay. Corrected hyponatremia was defined as mean serum sodium level during hospital stay ≥ 135 mmol/L in hyponatremic patients. De novo hyponatremia was defined as cases with mean serum sodium level during hospital stay \< 135 mmol/L in normonatremic patients. When mean serum sodium levels were ≥ 135 mmol/L in normonatremic patients and \< 135 mmol/L in hyponatremic patients, we defined these as persistent normonatremia and hyponatremia, respectively.

Serum creatinine was measured using the rate-blanked compensated kinetic alkaline picrate Jaffe method with an automatic analyzer (Toshiba-200FR, Tokyo, Japan). The between-day coefficients of variation for serum creatinine were 1.5--2.6% and 1.1--2.4% at low (168.0--176.8 μmol/L), and high concentrations (583.4--627.6 μmol/L), respectively, throughout the study periods. The estimated glomerular filtration rate (eGFR) was calculated by using the equation of the Chronic Kidney Disease Epidemiology Collaboration \[[@pone.0162990.ref031]\]. Baseline creatinine was defined as the lowest value within 6 months before the index admission or the calculated value from the Modification of Diet in Renal Disease study equation, assuming GFR 75 ml/min/1.73 m^2^ if creatinine was not available \[[@pone.0162990.ref032]\]. AKI was defined as a rise in serum creatinine by ≥ 26.5 mg/dL, or ≥ 1.5 times from the baseline level determined during the hospital stay \[[@pone.0162990.ref033], [@pone.0162990.ref034]\]. We classified a rise in serum creatinine by ≥ 2 times from the baseline as severe AKI. If the first creatinine of the index admission met the criteria for AKI, we defined it as a community acquired AKI. In-hospital patient mortality was determined by whether a death certificate had been issued at 90 days after admission. ESRD development was determined from the registry database of the Korean Society of Nephrology, and 1 year-mortality was determined from the database of Ministry of the interior.

Statistical analysis {#sec009}
--------------------

Values were expressed as mean ± SD or median (interquartile range, IQR) for continuous variables and percentage for categorical variables. The difference was analyzed by Student\`s *t* test for continuous variables and the chi-square test for categorical variables. *P*-trend was assessed by a linear-by-linear association. *P* \< 0.05 was considered to have statistical significance. For the estimated survival, the Kaplan-Meier method was employed, and the statistical significance was calculated using the log-rank test. The risk of a certain factor for AKI or in-hospital mortality was assessed using Cox proportional hazard regression analysis reporting hazard ratio (HR) and its confidence interval (CI). The assumption of proportional hazards was tested by log minus log plot for categorical variables and interaction analysis with time covariate using time-dependent Cox regression for continuous variables. All covariates entered into the model fulfilled the assumption. Since known risk factors for AKI or mortality were generally statistically significant in this study, we entered variables with *P* \< 0.05 in univariate analysis and missing rate \< 15% into the multivariate modeling to avoid over-adjustment. The multiplicative interaction was evaluated by entering the interaction term as a covariate in logistic regression analysis. The additive interaction was assessed by Relative Excess Risk due to Interaction (RERI), Attributable Proportion due to interaction (AP) and Synergistic Index (SI) \[[@pone.0162990.ref035]\] using R statistics (Version 3.0.3, R foundation for Statistical Computing Platform). Unless specified, all analysis was performed using SPSS Statistics (version 22; IBM, USA).

Results {#sec010}
=======

Of 19191 patients, the mean age was 58.1 ± 17.0 years and 52.4% were men. In total, 17.8% had hypertension, 20.3% had diabetes, 13.5% had cardiovascular disease, and 24.8% had cancer. In this population, 8.2% were hyponatremic initially. During a median (IQR) 6.0 (3.0--10.0) days of hospital stay, 5.1% experienced AKI of all stages, and 0.9% died from all causes within 90 days after admission. No patient died before the development of AKI. Among patients with the development of AKI or in-hospital mortality, the median (IQR) duration from the admission date to the development of AKI and in-hospital mortality were 5.0 (2.0--10.0) days and 13.6 (6.7--27.3) days, respectively.

Characteristics of hyponatremia and AKI group {#sec011}
---------------------------------------------

We compared baseline characteristics according to the status of hyponatremia ([Table 1](#pone.0162990.t001){ref-type="table"}). Older age and male were associated with hyponatremia. Patients with hyponatremia showed higher proportions of hypertension, diabetes, and cancer, and a lower proportion of cardiovascular disease than those with normonatremia. RAS inhibitors and diuretics use were associated with hyponatremia. Hyponatremic patients had lower body mass index, systolic and diastolic blood pressure (BP) and higher serum glucose than normonatremic patients. Patients with hyponatremia revealed significantly higher levels of inflammation, as indicated by white blood cells, NLR, RDW, and CRP, than those with normonatremia. Hemoglobin levels were significantly lower in the hyponatremic group than in the normonatremic group. Hyponatremic patients had lower eGFRs than normonatremic patients.

10.1371/journal.pone.0162990.t001

###### Baseline characteristics of sodium group.

![](pone.0162990.t001){#pone.0162990.t001g}

                                                                      Normonatremia (n = 17624)   Hyponatremia (n = 1567)   *P*
  ------------------------------------------------------------------- --------------------------- ------------------------- ----------
  Age (years)                                                         57.4 ± 16.9                 65.4 ± 16.3               \< 0.001
  Male sex                                                            9156 (52.0)                 908 (57.9)                \< 0.001
  Hypertension                                                        3022 (17.1)                 395 (25.2)                \< 0.001
  Diabetes                                                            3317 (18.8)                 570 (36.4)                \< 0.001
  Cardiovascular disease                                              2431 (13.8)                 165 (10.5)                \< 0.001
  Congestive heart failure                                            147 (0.8)                   27 (1.7)                  \< 0.001
  Liver disease                                                       1061 (6.0)                  143 (9.1)                 \< 0.001
  Cancer                                                              4229 (24.0)                 538 (34.3)                \< 0.001
  RAS inhibitor                                                       1210 (6.9)                  166 (10.6)                \< 0.001
  Diuretics                                                           705 (4.0)                   162 (10.3)                \< 0.001
  Body mass index (kg/m^2^)[\*](#t001fn003){ref-type="table-fn"}      23.9 ± 3.6                  22.3 ± 4                  \< 0.001
  Systolic BP (mmHg)[\*](#t001fn003){ref-type="table-fn"}             130.7 ± 20.5                127.3 ± 22.3              \< 0.001
  Diastolic BP (mmHg)[\*](#t001fn003){ref-type="table-fn"}            75.6 ± 13.5                 71.8 ± 14                 \< 0.001
  Sodium (mmol/L)                                                     139.4 ± 2.2                 131.2 ± 3.6               \< 0.001
  Glucose (mmol/L)[\*](#t001fn003){ref-type="table-fn"}               6.9 ± 2.6                   8.6 ± 5.2                 \< 0.001
  White blood cells (10^3^/μL)[\*](#t001fn003){ref-type="table-fn"}   8.2 ± 5.5                   9.8 ± 7.2                 \< 0.001
  Hemoglobin (g/dL)[\*](#t001fn003){ref-type="table-fn"}              12.8 ± 2                    11.7 ± 2.2                \< 0.001
  Platelet (10^3^/μL)[\*](#t001fn003){ref-type="table-fn"}            217.5 ± 77.6                223.8 ± 105.5             0.021
  NLR[\*](#t001fn003){ref-type="table-fn"}                            4.8 ± 5.2                   7.4 ± 7.9                 \< 0.001
  RDW (%)[\*](#t001fn003){ref-type="table-fn"}                        13.6 ± 1.7                  14.2 ± 2.2                \< 0.001
  C-reactive protein (nmol/L)[\*](#t001fn003){ref-type="table-fn"}    467.6 ± 567.5               717.6 ± 697.8             \< 0.001
  Protein (g/L)[\*](#t001fn003){ref-type="table-fn"}                  65.7 ± 7.9                  63.4 ± 8.8                \< 0.001
  Albumin (g/L)[\*](#t001fn003){ref-type="table-fn"}                  39.7 ± 5.7                  35.2 ± 6.2                \< 0.001
  Cholesterol (mmol/L)[\*](#t001fn003){ref-type="table-fn"}           4.5 ± 1.2                   4.1 ± 1.5                 \< 0.001
  Bilirubin (μmol/L)[\*](#t001fn003){ref-type="table-fn"}             13.8 ± 19.6                 22.2 ± 43.1               \< 0.001
  Blood urea nitrogen (mmol/L)[\*](#t001fn003){ref-type="table-fn"}   5.3 ± 2.5                   6.0 ± 3.6                 \< 0.001
  Serum creatinine (μmol/L)                                           78.4 ± 32.8                 80.1 ± 55.6               0.248
  eGFR (ml/min/1.73m^2^)                                              86.3 ± 18.5                 83.8 ± 22.5               \< 0.001

RAS, renin angiotensin system; BP, blood pressure; NLR, neutrophil to lymphocyte ratio; RDW, red cell distribution width; eGFR, estimated glomerular filtration rate.

Values are expressed as mean ± standard deviation for continuous variables and n (%) for categorical variables. Comparisons were made by chi square for categorical variables or *Student t*-test for continuous variables.

\* Incomplete data. The missing data rate was 9.4% in body mass index, 0.3% in systolic and diastolic BP, 12.2% in glucose, 1.1% in white blood cells, hemoglobin and platelet, 30.2% in NLR and RDW, 44.4% in C-reactive protein, 2.2% in protein, 1.5% in albumin, 2.1% in cholesterol, 1.5% in bilirubin and 0.2% in blood urea nitrogen.

We also explored factors associated with AKI development ([Table 2](#pone.0162990.t002){ref-type="table"}). Older age, male, and the presence of comorbidities were related to AKI development. RAS inhibitors and diuretics were associated with AKI development. Patients with AKI showed higher levels of serum glucose and inflammation than those without AKI. The AKI group had significantly lower levels of hemoglobin than the non-AKI group. Higher levels of blood urea nitrogen (BUN) were associated with AKI development. In multivariate Cox proportional hazard regression analysis, male, diabetes, congestive heart failure, diuretics use, diastolic BP, and levels of hemoglobin, protein, albumin, bilirubin, and BUN were associated with AKI development.

10.1371/journal.pone.0162990.t002

###### Factors associated with acute kidney injury development.

![](pone.0162990.t002){#pone.0162990.t002g}

                                                                                                  Univariate                      Multivariate[†](#t002fn004){ref-type="table-fn"}                          
  ----------------------------------------------------------------------------------------------- --------------- --------------- -------------------------------------------------- ---------------------- ----------
  Age (years)[‡](#t002fn005){ref-type="table-fn"}                                                 57.7 ± 17.0     65.3 ± 15.6     \< 0.001                                           1.118 (0.954--1.310)   0.168
  Male sex                                                                                        9501 (52.2)     563 (57.7)      0.001                                              1.262 (1.088--1.465)   0.002
  Hypertension                                                                                    3148 (17.3)     269 (27.6)      \< 0.001                                           1.015 (0.822--1.253)   0.891
  Diabetes                                                                                        3449 (18.9)     438 (44.9)      \< 0.001                                           1.885 (1.622--2.192)   \< 0.001
  Cardiovascular disease                                                                          2445 (13.4)     151 (15.5)      0.068                                              \-                     \-
  Congestive heart failure                                                                        129 (0.7)       45 (4.6)        \< 0.001                                           2.986 (2.072--4.303)   \< 0.001
  Liver disease                                                                                   1136 (6.2)      68 (7.0)        0.359                                              \-                     \-
  Cancer                                                                                          4443 (24.4)     324 (33.2)      \< 0.001                                           1.088 (0.935--1.265)   0.275
  RAS inhibitor                                                                                   1269 (7.0)      107 (11.0)      \< 0.001                                           1.026 (0.786--1.340)   0.850
  Diuretics                                                                                       754 (4.1)       113 (11.6)      \< 0.001                                           1.514 (1.151--1.993)   0.003
  Body mass index (kg/m^2^)[\*](#t002fn003){ref-type="table-fn"}                                  23.8 ± 3.7      23.2 ± 4.0      \< 0.001                                           1.000 (0.982--1.018)   0.991
  Systolic BP (mmHg)[\*](#t002fn003){ref-type="table-fn"}                                         130.4 ± 20.4    130.9 ± 25.0    0.562                                              \-                     \-
  Diastolic BP (mmHg)[\*](#t002fn003){ref-type="table-fn"}                                        75.4 ± 13.5     74 ± 15.2       0.006                                              1.006 (1.001--1.011)   0.016
  Hyponatremia                                                                                    1366 (7.5)      201 (20.6)      \< 0.001                                           1.300 (1.086--1.555)   0.004
  Sodium (mmol/L)                                                                                 138.8 ± 3.1     137.1 ± 4.7     \< 0.001                                           \-                     \-
  Glucose (mmol/L)[\*](#t002fn003){ref-type="table-fn"}[‡](#t002fn005){ref-type="table-fn"}       7.0 ± 2.9       8.0 ± 4.1       \< 0.001                                           1.030 (0.890--1.192)   0.695
  WBC (10^3^/μL)[\*](#t002fn003){ref-type="table-fn"}                                             8.3 ± 5.5       9.5 ± 7.7       \< 0.001                                           1.006 (0.997--1.014)   0.185
  Hemoglobin (g/dL)[\*](#t002fn003){ref-type="table-fn"}                                          12.8 ± 2.0      11.8 ± 2.3      \< 0.001                                           0.959 (0.921--0.998)   0.038
  Platelet (10^3^/μL)[\*](#t002fn003){ref-type="table-fn"}[‡](#t002fn005){ref-type="table-fn"}    218.2 ± 78.6    214.2 ± 105.6   0.247                                              \-                     \-
  NLR[\*](#t002fn003){ref-type="table-fn"}[‡](#t002fn005){ref-type="table-fn"}                    4.9 ± 5.3       7.3 ± 8.7       \< 0.001                                           \-                     \-
  RDW (%)[\*](#t002fn003){ref-type="table-fn"}                                                    13.6 ± 1.8      14.3 ± 1.9      \< 0.001                                           \-                     \-
  CRP (nmol/L)[\*](#t002fn003){ref-type="table-fn"}                                               482.9 ± 578.5   628.0 ± 674.2   \< 0.001                                           \-                     \-
  Protein (g/L)[\*](#t002fn003){ref-type="table-fn"}                                              65.6 ± 7.9      63.1 ± 9.0      \< 0.001                                           1.013 (1.003--1.023)   0.012
  Albumin (g/L)[\*](#t002fn003){ref-type="table-fn"}                                              39.5 ± 5.8      35.8 ± 6.6      \< 0.001                                           0.948 (0.933--0.964)   \< 0.001
  Cholesterol (mmol/L)[\*](#t002fn003){ref-type="table-fn"}[‡](#t002fn005){ref-type="table-fn"}   4.5 ± 1.2       4.1 ± 1.4       \< 0.001                                           1.072 (0.917--1.253)   0.385
  Bilirubin (μmol/L)[\*](#t002fn003){ref-type="table-fn"}                                         14.0 ± 19.9     23.7 ± 50.5     \< 0.001                                           1.003 (1.001--1.004)   \< 0.001
  BUN (mmol/L)[\*](#t002fn003){ref-type="table-fn"}[‡](#t002fn005){ref-type="table-fn"}           5.3 ± 2.5       7.0 ± 4.5       \< 0.001                                           1.559 (1.352--1.798)   \< 0.001
  Serum creatinine (μmol/L)                                                                       78.3 ± 31.3     82.7 ± 78.1     0.082                                              \-                     \-
  eGFR (ml/min/1.73m^2^)[‡](#t002fn005){ref-type="table-fn"}                                      86.1 ± 18.2     86.0 ± 28.9     0.201                                              \-                     \-
  eGFR ≥ 86.1 ml/min/17.3m^2^[^\$^](#t002fn006){ref-type="table-fn"}                              7725 (42.4)     430 (44.1)      0.310                                              \-                     \-
  eGFR (min.--max.)                                                                               2.4--210.4      3.4--193.2      \-                                                 \-                     \-

HR, hazard ratio; CI, confidence interval; RAS, renin angiotensin system; BP, blood pressure; WBC, white blood cells; NLR, neutrophil to lymphocyte ratio; RDW, red cell distribution width; CRP, c-reactive protein; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate.

Values are expressed as mean ± standard deviation for continuous variables and n (%) for categorical variables. Comparisons were made by chi-square test for categorical variables or *Student t*-test for continuous variables. HRs for categorical and continuous variables were "yes vs. no" and "per 1 unit increase", respectively.

\* Incomplete data. The missing data rate was 9.4% in body mass index, 0.3% in systolic and diastolic BP, 12.2% in glucose, 1.1% in white blood cells, hemoglobin and platelet, 30.2% in NLR and RDW, 44.4% in CRP, 2.2% in protein, 1.5% in albumin, 2.1% in cholesterol, 1.5% in bilirubin and 0.2% in BUN.

^†^Cox proportional hazard regression analysis entering variables with *P* \< 0.05 in univariate analysis and missing rate \< 15%.

^‡^ Not fulfilling the proportional hazard assumption as continuous variables, but fulfilling the assumption as categorical variables by their mean value in whole patients: 58.7 years for age, 7.1 mmol/L for glucose, 5.3 for NLR, 4.4 mmol/L for cholesterol, and 6.0 mmol/L for BUN. The reported HRs were above vs. below the mean.

^\$^ Mean of eGFR in whole population.

Hyponatremia, AKI and mortality {#sec012}
-------------------------------

Hyponatremic patients showed significantly higher incidence rates of AKI than normonatremic patients ([Fig 2](#pone.0162990.g002){ref-type="fig"}). Patients with AKI had considerably lower serum sodium levels than patients without AKI ([Table 2](#pone.0162990.t002){ref-type="table"}). After adjusting for covariates including age, male, hypertension, diabetes, congestive heart failure, cancer, RAS inhibitors, diuretics, body mass index, diastolic BP, white blood cells, hemoglobin, and serum levels of glucose, protein, albumin, cholesterol, bilirubin, and BUN, hyponatremia was independently associated with the increased risk of AKI development with HR 1.300 (95% CI, 1.086--1.555; *P* = 0.004) in multivariate Cox proportional hazard regression.

![Clinical outcomes according to sodium group.\
\* means *P* \< 0.001 compared to normonatremia group. Error bar indicates standard error. AKI, acute kidney injury; ESRD, end stage renal disease.](pone.0162990.g002){#pone.0162990.g002}

Hyponatremic patients had considerably poorer patient survival rates than normonatremic patients ([Fig 3A](#pone.0162990.g003){ref-type="fig"}). Patients with AKI also showed significantly shorter patient survival times than those without AKI ([Fig 3B](#pone.0162990.g003){ref-type="fig"}). Both hyponatremia and AKI were significantly related to the increased risk of in-hospital mortality with HRs (95% CI) of 2.481 (1.381--4.459, *P* = 0.002) and 7.338 (4.727--11.391, *P* \< 0.001) in multivariate Cox proportional hazard regression analysis ([Table 3](#pone.0162990.t003){ref-type="table"}). Since hyponatremia was related to AKI development, we explored the interaction between hyponatremia and AKI for the development of in-hospital mortality ([Table 4](#pone.0162990.t004){ref-type="table"}). Compared to the patients with normonatremia and no AKI, patients with pre-exisiting hyponatremia and patients with AKI had worse in-hospital mortality (OR 7.515, *P* \< 0.001; OR 45.69, *P* \< 0.001, respectively) ([Table 4](#pone.0162990.t004){ref-type="table"}). Pre-existing hyponatremia and subsequent development of AKI increased the risk of short-term morality by 85.55 times, compared to the controls, although not statistically significant in RERI. We compared patient survival for different sodium levels and the presence of AKI ([Fig 3C](#pone.0162990.g003){ref-type="fig"}).

![Cumulative survival rate according to sodium (Na) and acute kidney injury (AKI) groups.\
A, B and C show survival curves of sodium, AKI and combined sodium and AKI groups for the in-hospital mortality, respectively. \* and † indicate *P* \< 0.001 when compared to normonatremic patients without AKI and hyponatremic patients without AKI groups, respectively, and ‡ indicates *P* \< 0.05 when compared to normonatremic with AKI group using log-rank test.](pone.0162990.g003){#pone.0162990.g003}

10.1371/journal.pone.0162990.t003

###### Hazard ratio for in-hospital mortality in Cox proportional hazard regression.

![](pone.0162990.t003){#pone.0162990.t003g}

                                                          Univariate                         Multivariate            
  ------------------------------------------------------- ----------------------- ---------- ----------------------- ----------
  Age (years)                                             1.044 (1.032--1.056)    \< 0.001   1.025 (1.011--1.039)    \< 0.001
  Male sex                                                1.339 (0.987--1.818)    0.061      \-                      \-
  Hypertension                                            1.742 (1.262--2.405)    0.001      1.034 (0.627--1.707)    0.895
  Diabetes                                                2.351 (1.731--3.192)    \< 0.001   1.140 (0.793--1.639)    0.479
  Cardiovascular disease                                  2.177 (1.540--3.077)    \< 0.001   2.209 (1.428--3.416)    \< 0.001
  Congestive heart failure                                3.801 (1.869--7.729)    \< 0.001   0.743 (0.285--1.939)    0.544
  Liver disease                                           1.106 (0.565--2.165)    0.768      \-                      \-
  Cancer                                                  1.654 (1.225--2.233)    0.001      1.916 (1.331--2.758)    \< 0.001
  RAS inhibitor                                           1.751 (1.087--2.820)    0.021      0.915 (0.500--1.674)    0.774
  Diuretics                                               3.293 (2.155--5.031)    \< 0.001   1.543 (0.829--2.873)    0.171
  BMI ≥23.7 kg/m^2^[†](#t003fn004){ref-type="table-fn"}   0.393 (0.270--0.571)    \<0.001    0.500 (0.341--0.734)    \< 0.001
  SBP ≥130.2 mmHg[†](#t003fn004){ref-type="table-fn"}     0.659 (0.485--0.897)    0.008      0.666 (0.455--0.975)    0.037
  DBP ≥74.9 mmHg[†](#t003fn004){ref-type="table-fn"}      0.627 (0.462--0.852)    0.003      1.138 (0.784--1.652)    0.497
  Glucose (mmol/L)                                        1.072 (1.042--1.103)    \< 0.001   1.007 (0.965--1.051)    0.746
  WBC (10^3^/μL)                                          1.020 (1.013--1.026)    \< 0.001   1.017 (1.007--1.027)    0.001
  Hemoglobin (g/dL)                                       0.849 (0.796--0.906)    \< 0.001   1.047 (0.959--1.143)    0.308
  Platelet (10^3^/μL)                                     0.996 (0.994--0.998)    \< 0.001   0.998 (0.996--0.999)    0.009
  NLR[\*](#t003fn003){ref-type="table-fn"}                1.037 (1.028--1.046)    \< 0.001   \-                      \-
  RDW (%)[\*](#t003fn003){ref-type="table-fn"}            1.232 (1.174--1.293)    \< 0.001   \-                      \-
  CRP (nmol/L)[\*](#t003fn003){ref-type="table-fn"}       1.001 (1.001--1.001)    \< 0.001   \-                      \-
  Protein (g/L)                                           0.964 (0.949--0.979)    \< 0.001   1.005 (0.984--1.026)    0.625
  Albumin ≥ 39 g/L[†](#t003fn004){ref-type="table-fn"}    0.290 (0.200--0.420)    \<0.001    0.456 (0.279--0.746)    0.002
  Cholesterol (mmol/L)                                    0.664 (0.580--0.759)    \< 0.001   0.869 (0.757--0.997)    0.045
  Bilirubin (μmol/L)                                      1.003 (1.001--1.006)    0.004      1.002 (1.000--1.005)    0.088
  BUN ≥ 6.0 mmol/L [†](#t003fn004){ref-type="table-fn"}   2.730 (2.009--3.708)    \<0.001    1.301 (0.915--1.850)    0.143
  eGFR (ml/min/1.73m^2^)                                  0.993 (0.987--1.000)    0.051      \-                      \-
  Hyponatremia                                            2.915 (2.121--4.006)    \< 0.001   2.481 (1.381--4.459)    0.002
  AKI                                                     8.711 (6.273--12.097)   \< 0.001   7.338 (4.727--11.391)   \< 0.001

HR, hazard ratio; CI, confidence interval; RAS, renin angiotensin system; BP, blood pressure; WBC, white blood cells; NLR, neutrophil to lymphocyte ratio; RDW, red cell distribution width; CRP, c-reactive protein; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; AKI, acute kidney injury.

HRs for categorical and continuous variables were "yes vs. no" and "per 1 unit increase", respectively. Interaction term between hyponatremia and AKI was statistically significant in both univariate (*P* = 0.001) and multivariate (*P* = 0.024) analysis. Variables with *P* \< 0.05 in univariate analysis and missing rate \< 15.0% were entered into multivariate analysis.

\* Missing rate ≥15.0%

^†^ Not fulfilling the proportional hazard assumption as continuous variables, but fulfilling the assumption as categorical variables by their mean value in whole patients.

10.1371/journal.pone.0162990.t004

###### Interaction analysis between hyponatremia and acute kidney injury for the in-hospital mortality.

![](pone.0162990.t004){#pone.0162990.t004g}

                                                                         AKI        OR (95% CI) for AKI (yes vs. no) within strata of sodium group                                       
  ---------------------------------------------------------------------- ---------- ---------------------------------------------------------------- -------- -------------------------- -------------------------
  No                                                                     40/16809   1.0 (reference)                                                  76/699   45.690 (30.926--67.501)    45.690 (30.926--67.501)
  Yes                                                                    24/1342    7.515 (4.517--12.504)                                            34/167   85.554 (52.838--138.529)   11.384 (6.590--19.667)
  OR (95% CI) for hyponatremia (yes vs. no) within strata of AKI group              7.515 (4.517--12.504)                                                     1.873 (1.208--2.902)       

Measure of interaction on additive scale: RERI (95% CI) 33.350 (-1.611--68.311), AP (95% CI) 0.390 (0.129--0.650) and SI (95% CI) 1.651 (1.071--2.546); Measure of interaction on multiplicative scale: OR (95% CI) 0.249 (0.127--0.488). ORs are unadjusted. OR, odd ratio; CI, confidence interval; AKI, acute kidney injury; RERI, relative excess risk due to interaction; AP, attributable proportion due to interaction; SI, synergistic index.

\*with/without in-hospital mortality

The hyponatremia & non-AKI, normonatremia & AKI, and hyponatremia & AKI groups showed significantly poorer patient survival than the normonatremia & non-AKI group. This was still evident in multivariate Cox proportional hazard regression analysis adjusting for the same variables in [Table 3](#pone.0162990.t003){ref-type="table"}. HRs (95% CI) for the hyponatremia & non-AKI, normonatremia & AKI, and hyponatremia & AKI groups vs. the normonatremia & non-AKI group for the in-hospital mortality were 2.481 (1.381--4.458, *P* = 0.002), 7.338 (4.727--11.391, *P* \< 0.001) and 7.951 (4.677--13.515, *P* \< 0.001), respectively.

As one of the overcorrection variables, we evaluated de novo hypernatremia. Of 18353 patients who had serial data of serum sodium levels, we found 405 patients with de novo hypernatremia (2.1%). De novo hypernatremia was also significantly associated with in-hospital mortality with HR 3.297 (95% CI 2.264--4.800, *P* \<0.001) in a multivariate Cox proportional hazard regression model. Meanwhile, patients with AKI (16.2%) showed significantly higher rates of de novo hypernatremia than patients without AKI (1.4%; *P* \< 0.001). Through examining different combinations of sodium levels and AKI, we identified a significant tendency of an increased rate of de novo hypernatremia across the normonatremia & non-AKI, hyponatremia & non-AKI, normonatremia & AKI and hyponatremia & AKI groups ([Fig 4](#pone.0162990.g004){ref-type="fig"}).

![Proportion of de novo hypernatremia depending on the status of combined sodium (Na) and acute kidney injury (AKI) group.\
Error bar indicates standard error. \* indicates *P* \< 0.05 by chi-square test when compared to the normoNa & non-AKI group.](pone.0162990.g004){#pone.0162990.g004}

Hyponatremic patients also showed a significantly higher risk of severe AKI, 1-year ESRD, and 1-year mortality than normonatremic patients ([Fig 2](#pone.0162990.g002){ref-type="fig"}).

Effect of hyponatremia correction {#sec013}
---------------------------------

Of 18353 patients who had serial data on serum sodium levels, 84.5%, 3.1%, 2.2% and 5.9% were classified as persistent normonatremia, de novo hyponatremia, corrected hyponatremia, and persistent hyponatremia groups, respectively. Patients with persistent normonatremia showed consistently lower risks of AKI development and in-hospital mortality than those with corrected hyponatremia. Patients with de novo hyponatremia still had a lower risk of in-hospital mortality than those with corrected hyponatremia. The risks of AKI development and in-hospital mortality were not different between patients with persistent and corrected hyponatremia ([Table 5](#pone.0162990.t005){ref-type="table"}).

10.1371/journal.pone.0162990.t005

###### Hazard ratio of hyponatremia correction group for the development of acute kidney injury and in-hospital mortality in multivariate Cox proportional hazard regression analysis.
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                               For AKI development    For in-hospital mortality                          
  ---------------------------- ---------------------- --------------------------- ---------------------- -------
  vs. Corrected hyponatremia                                                                             
  Persistent normonatremia     0.606 (0.457--0.803)   \< 0.001                    0.514 (0.312--0.846)   0.009
  De novo hyponatremia         0.894 (0.643--1.242)   0.505                       0.504 (0.264--0.964)   0.038
  Persistent hyponatremia      0.793 (0.578--1.088)   0.151                       0.590 (0.327--1.065)   0.080

AKI, acute kidney injury; HR, hazard ratio; CI, confidence interval.

Variables with *P* \< 0.05 in univariate analysis and missing rate \< 15.0% were entered into the analysis. All covariates entered fulfilled the assumption of proportional hazard.

Discussion {#sec014}
==========

Hyponatremia in hospitalized patients is common \[[@pone.0162990.ref001], [@pone.0162990.ref036]\], and may increase the risk of mortality in various conditions. AKI is a common and dangerous, but correctable, disease. The two clinical conditions may share various comorbidities, and there is a high chance of cross-talk among hyponatremia, AKI and mortality. Therefore, we investigated whether pre-existing hyponatremia may be associated with the development of AKI during the hospital stay. We also evaluated whether hospital acquired AKI modified the effect of hyponatremia on short-term patients mortality.

One of the major findings is that hyponatremic patients have approximately a 1.3-fold higher risk of AKI development than normonatremic patients. Sodium levels reflect on the homeostasis of water regulation in the body \[[@pone.0162990.ref001], [@pone.0162990.ref020]\]. Hyponatremia may be related to unbalanced condition of extracellular water, major organ failure or septic conditions \[[@pone.0162990.ref001], [@pone.0162990.ref003], [@pone.0162990.ref004], [@pone.0162990.ref037]\], which are some of main causes in hospital acquired AKI \[[@pone.0162990.ref013]--[@pone.0162990.ref018]\]. The higher rates of AKI risk factors \[[@pone.0162990.ref038]\] in hyponatremic patients than in normonatremic patients might affect the association between hyponatremia and AKI development. In addition, the higher levels of inflammation found in hyponatremic patients might explain the increased risk of AKI development with hyponatremia. With our study, we cannot conclude whether hyponatremia has causal relationship for the AKI development or not. However, we postulate hyponatremia might be a simple "association", not a causative factor for AKI development since patients with persistent normonatremia showed lower risk for AKI development than patients with corrected hyponatremia. Although further study is needed to confirm this result, one thing which can be stated is that patients with pre-existing hyponatremia may need to be periodically monitored with serum creatinine levels or urine outputs for AKI development.

We observed that hyponatremia is an independent risk factor for in-hospital mortality (HR 2.481). Hyponatremia can influence on patient mortality \[[@pone.0162990.ref020]\]. However, if there would be some interaction between hyponatremia and AKI, these two combined pathologic conditions could contribute to dramatic increase in fatal outcomes. Since hyponatremia is tightly associated with AKI development and AKI is significantly associated with an increased risk of in-hospital mortality (HR 7.338) in our data, we examined whether there was a combined effect of hyponatremia and hospital acquired AKI on in-hospital mortality. In terms of clinical practice, it may be difficult to control patients homeostasis of electrolyte and fluid in patients with AKI \[[@pone.0162990.ref021], [@pone.0162990.ref022]\], which could be a potential explanation of this combined interaction between hyponatremia and AKI. We observed that the serum sodium level fluctuated more in patients with AKI than in those without AKI, since the AKI group showed higher rates of de novo hypernatremia than the non-AKI group by 11.6 fold. We also identified that patients with de novo hypernatremia showed a 3.297 times higher risk of in-hospital mortality than patients without de novo hypernatremia. Therefore it may demonstrate that the unstable sodium homeostasis in the AKI group could explain the combined effect between hyponatremia and AKI for in-hospital mortality.

Up to now, it has been uncertain whether patients die with or from hyponatremia. One meta-analysis suggested that the improvement of hyponatremia would revert or decrease the mortality risk related to hyponatremia \[[@pone.0162990.ref039]\]. However, not all the literature in the meta-analysis compared the corrected hyponatremia groups with persistent normonatremia. In fact, some studies clearly showed that the resolution of hyponatremia did not reduce the mortality risk \[[@pone.0162990.ref040]--[@pone.0162990.ref042]\], which is consistent with our results. Corrected hyponatremia did not reduce the risk of in-hospital mortality compared to persistent or de novo hyponatremia. The risk of in-hospital mortality between patients with corrected and persistent hyponatremia were similar. Therefore, further well-designed trials are still needed whether hyponatremia might be a bystander or a causative factor for in-hospital mortality.

There are some strengths of this study. First, the results were drawn from a very large administrative cohort. Second, all patients who admitted in this tertiary hospital were enrolled which minimized a selection bias. In addition, the clinical and laboratory data from the enrolled patients were available with low missing rate. Finally, we defined a baseline creatinine with the values 6 months before the admission which was not always possible in this large cohort study. However, the current study also has several limitations. First, we could not use glucose-adjusted serum sodium since not all patients had serum glucose assessed at the same time as serum sodium. Generally, every 100 mg/dL increase of serum glucose results in 2.4 mmol/L decrease of serum sodium levels \[[@pone.0162990.ref001]\]. However, the serum glucose levels of the study patients were not very high. Moreover, we used the serum glucose level as a covariate in multivariate analysis. Therefore, the effect of serum glucose on our study result should be minimal. Second, we defined AKI only by the creatinine criteria since not all patients had urine output recorded. Third, since this was retrospective, there were some uncertainties in information. We had little information on causes of AKI and death. Among patients with community acquired AKI who were excluded from this analysis, significant proportion of patients could be CKD patients. There is a chance to have other unmeasured confounders. Finally, the generalizability might be limited because this was a single-nation and single-center study.

We found that pre-existing hyponatremia may predict the development of AKI and in-hospital mortality, and that hyponatremia and AKI may lead to combined bad consequences such as in-hospital mortality, probably related to the unstable sodium homeostasis during the treatment period of hospital stay. It will be a possible option to reduce patient\`s event that hyponatremic patients need to monitor the development of AKI more frequently and to avoid overcorrection of hyponatremia in AKI patients.
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